Abstract:Sclerostin (Scl) is an osteocyte protein that decreases bone formation, and its inhibition by neutralizing antibodies (Scl-Ab) increases bone formation, mass and strength. We investigated the effects of Scl-Ab in mature ovariectomized (OVX) rats with a mechanistic focus on longer-term responses of osteoclasts, osteoblasts and osteocytes. Four-month-old Sprague-Dawley rats had OVX or sham surgery. Two months later, sham controls received sc vehicle while OVX rats received vehicle (OVX-Veh) or Scl-Ab (25mg/kg) once weekly for 6 or 26weeks followed by necropsy (n=12/group). Terminal blood was collected for biochemistry, non-adherent marrow cells were harvested from femurs for ex vivo osteoclast formation assays, and vertebrae and tibiae were collected for dynamic histomorphometry and mRNA analyses. Scl-Ab treatment led to progressively thicker but fewer trabeculae in the vertebra, leading to increased trabecular bone volume and reduced trabecular surfaces. Scl-Ab also increased cortical bone volume in the tibia, via early periosteal expansion and progressive endocortical contraction. Scl-Ab significantly reduced parameters of bone resorption at week 6 relative to OVX-Veh controls, including reduced serum TRACP-5b, reduced capacity of marrow cells to form osteoclasts ex vivo, and >80% reductions in vertebral trabecular and tibial endocortical eroded surfaces. At week 26, serum TRACP-5b and ex vivo osteoclast formation were no longer reduced in the Scl-Ab group, but eroded surfaces remained >80% lower than in OVX-Veh controls without evidence for altered skeletal mRNA expression of opg or rankl. Scl-Ab significantly increased parameters of bone formation at week 6 relative to OVX-Veh controls, including increases in serum P1NP and osteocalcin, and increased trabecular, endocortical and periosteal bone formation rates (BFRs). At week 26, surface-referent trabecular BFR remained significantly increased in the Scl-Ab group versus OVX-Veh controls, but after adjusting for a reduced extent of trabecular surfaces, overall (referent-independent) trabecular BFR was no longer significantly elevated. Similarly, serum P1NP and osteocalcin were no longer significantly increased in the Scl-Ab group at week 26. Tibial endocortical and periosteal BFR were increased at week 6 in the Scl-Ab group versus OVX-Veh controls, while at week 26 only endocortical BFR remained increased. The Scl-Ab group exhibited significant increments in skeletal mRNA expression of several osteocyte genes, with sost showing the greatest induction in both the tibia and vertebra. We propose that Scl-Ab administration, and/or the gains in bone volume that result, may have increased osteocytic expression of Scl as a possible means of regulating gains in bone mass.

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

Increased Risk of Low Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease: A Cohort Study

Osteocalcin and Non‐Alcoholic Fatty Liver Disease: Lessons From Two Population‐Based Cohorts and Animal Models

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Serum Sclerostin Levels Associated with Lumbar Spine Bone Mineral Density and Bone Turnover Markers in Patients with Postmenopausal Osteoporosis.

Serum Sclerostin Levels Were Positively Correlated with Fat Mass and Bone Mineral Density in Central South Chinese Postmenopausal Women

Reduced Femoral Bone Mass in Both Diet-Induced and Genetic Hyperlipidemia Mice

Upregulation of Caveolin-1 and SR-B1 in Mice with Non-Alcoholic Fatty Liver Disease

Sclerostin Antibody Mitigates Estrogen Deficiency-Inducted Marrow Lipid Accumulation Assessed By Proton Mr Spectroscopy

Effect of Alendronate Sodium on the Expression of Mesenchymal-Epithelial Transition Markers in Mice with Liver Fibrosis

In vitro osteoclast differentiation enhanced by hepatocyte supernatants from high-fat diet mice

The Role of Sclerostin in Lipid and Glucose Metabolism Disorders

Analysis of the Correlation Between Non-Alcoholic Fatty Liver Disease and Bone Metabolism Indicators in Healthy Middle-Aged Men

Low Levels of Osteocalcin, but Not CTX or P1NP, Are Associated with Nonalcoholic Hepatic Steatosis and Steatohepatitis.

Sclerostin Protects Against Vascular Calcification Development in Mice

Sclerostin Antibody Treatment Causes Greater Alveolar Crest Height and Bone Mass in an Ovariectomized Rat Model of Localized Periodontitis.

Low Bone Mineral Density in Chinese Adults with Nonalcoholic Fatty Liver Disease.

Association Between Sclerostin, Serum Bone Turnover Markers And Bone Density In Postmenopausal Women With Fragility Fracture

Sclerostin and Its Associations with Bone Metabolism Markers and Sex Hormones in Healthy Community-Dwelling Elderly Individuals and Adolescents

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats

Sclerostin Enhances Adipocyte Differentiation in 3T3‐L1 Cells